Key Takeaways
- Today, Nourish published data on GLP-1 medication persistence for patients in our program, examining the impact of integrated nutrition and lifestyle support on patients' ability to stay on medication long enough to see results.
- This data shows that 68% of Nourish patients are persistent at 6 months, meaningfully outperforming a 46% industry benchmark.
- This strong persistence data is a signal that integrated, dietitian-led care plays an important role in closing the persistence gap and ultimately helping patients realize the long-term benefits of GLP-1s.
GLP-1 medications have emerged as a powerful tool for patients managing obesity and metabolic disease, and their rapid adoption is reshaping the landscape of care. Despite this promise, a critical challenge remains when it comes to persistence. Most patients don't stay on these medications long enough to see their full clinical benefit. Real-world evidence shows fewer than half of patients are still on a GLP-1 at six months, and those who discontinue often regain a significant portion of the weight they lost.
At Nourish, our care model tackles this persistence gap directly. Our dietitian-led approach pairs GLP-1 therapy with personalized nutrition support at every stage of a patient's medication journey, addressing the clinical and lifestyle barriers that can result in patients stopping treatment prematurely.
The data shows this model is working. For Nourish patients on GLP-1s, our outcomes show 68% persistence at six months, compared to a 46% industry benchmark. This data represents a meaningful signal that integrated, nutrition-first care can improve GLP-1 outcomes at scale.
Read the full whitepaper here.
Do you have any of these insurances?
Why Join Nourish's RD Network
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
